HIV in suicide mode! In a breakthrough,
researchers, including an Indian origin scientist, have created a microbicide
that can trick HIV into killing itself without disturbing any healthy cells.
A team of Drexel University researchers is
trying to get one step ahead of the virus with a microbicide they've created
that can trick HIV into "popping" itself into oblivion. The
microbicide DAVEI - which stands for "Dual Action Virolytic Entry
Inhibitor" - is the latest in a new generation of HIV treatments that
function by specifically destroying the virus without harming healthy cells,
researchers said.
Pinning down an effective way to combat the
spread of the human immunodeficiency virus, the viral precursor to AIDS, has
long been a challenge for scientists and physicians, because the virus is an
elusive one that mutates frequently and, as a result, quickly becomes immune to
medication.
"While several molecules that destroy HIV have recently been
announced, DAVEI is unique among them by virtue of its design, specificity and
high potency," said Dr Cameron Abrams, a professor in Drexel's College of
Engineering and a primary investigator of the project.
A team co-led by Abrams and Dr Irwin Chaiken in the Department of
Biochemistry and Molecular Biology in Drexel's College of Medicine, and
including R V Kalyana Sundaram, developed the chimeric recombinantly engineered
protein - that is, a molecule assembled from pieces of other molecules and
engineered for a specific purpose, in this case to fight HIV.
HIV invades a healthy cell by first attaching via protein
"spikes" that then collapse to pull viral and cell membranes
together, fusing them and allowing the genetic contents of the virus to enter
the healthy cell.
The cell is rewired by the viral genetic material into producing more
viruses instead of performing its normal function, which, in the case of cells
infected by HIV, involves normal immunity. AIDS is the result.
"We hypothesised that an important role of the fusion machinery
is to open the viral membrane when triggered, and it follows that a trigger
didn't necessarily have to be a doomed cell," Abrams said.
"So we envisioned particular ways the components of the viral
fusion machinery work and designed a molecule that would trigger it
prematurely," Abrams said.
The team designed DAVEI from two main ingredients. One piece, called
the Membrane Proximal External Region (MPER), is itself a small piece of the
fusion machinery and interacts strongly with viral membranes.
The other piece, called cyanovirin, binds to the sugar coating of the
protein spike. Working together, the MPER and cyanovirin in DAVEI
"tweak" the fusion machinery in a way that mimics the forces it feels
when attached to a cell.
The study was published in the journal Antimicrobial Agents and
Chemotherapy.
No comments:
Post a Comment